Sutent + Taxol for Advanced Esophageal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Esophageal Cancer
Interventions
DRUG

Sunitinib malate

Sunitinib malate 37.5 mg orally, daily

DRUG

Paclitaxel

Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.

Trial Locations (15)

44106

Ireland Cancer Center - University Hospitals of Cleveland, Cleveland

46202

IN Onc/Hem Associates, Indianapolis

Indiana University Simon Cancer Center, Indianapolis

46321

Monroe Medical Associates, Munster

46601

Northern Indiana Cancer Research Consortium, South Bend

46815

Fort Wayne Oncology & Hematology, Inc, Fort Wayne

47303

Medical Consultants, P.C., Muncie

47403

Cancer Care Center of Southern Indiana, Bloomington

47714

Oncology Hematology Associates of SW Indiana, Evansville

47802

Providence Medical Group, Terre Haute

47904

Arnett Cancer Care, Lafayette

47905

Horizon Oncology Center, Lafayette

60611

Northwestern University Feinberg School of Medicine, Chicago

60612

Rush-Presbyterian St. Luke's Medical Center, Chicago

61401

Medical & Surgical Specialists, LLC, Galesburg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Hoosier Cancer Research Network

OTHER